Celgene owns 14.5% of Epizyme ahead of the initial public offering (IPO), after investing the portfolio company's series C round.

Stanford spin-out Tableau Software raises $254.2m in initial public offering.

Lanxess-backed converter of feedstocks into chemicals revises IPO terms.

Biogen Idec-backed Portola Pharmaceuticals set to raise around $103.2m on Nasdaq with $469m market cap

Receptos raised $73m in its initial public offering (IPO) on the Nasdaq stock exchange.

In February, Aratana raised $12m in its series C round.

The investment banks for the flotation are: Morgan Stanley, Goldman Sachs, JPMorgan Chase and Barclays.

Investment banks Cowan and BMO Capital Markets are advising the initial public offering (IPO), with legal counsel from Lowenstein Sandler and Goodwin Procter.

Ambit plans to list 4.645 million shares at between $13 and $15 each when it floats on the Nasdaq stock exchange.

The company priced 12.5 million American depository shares at $17 each, after having filed to sell 12 million shares at between $16 and $18 each.